Enrolling Studies
See a list of our enrolling studies and research information. Access current studies and clinical trial data.
Treatment Naïve and Previously Treated Wet AMD
Sponsor: Ocular Therapeutix OTX-LR
Study Drug: Sustained-release Tyrosine Kinase Inhibitor (Intravitreal Injection)
Control Arm: Aflibercept 50y/o
Inclusion/Exclusion Criteria: BCVA-20/80 or better in study eye, 20/200 or better in fellow eye CST-<500um Other: Sponsor covers fellow eye treatment (any drug) [/av_toggle] [av_toggle title='Previously-treated Wet AMD' title_open='' tags='' title_pos='' slide_speed='' custom_id='' aria_collapsed='' aria_expanded='' av_uid='av-ncqnvm' sc_version='1.0'] Sponsor: Regenxbio Study Drug: Subretinal Gene Therapy (coding for Ranibizumab) (Surgical) Control Arm: Ranibizumab or Aflibercept Inclusion/Exclusion Criteria: BCVA- 20/40-20/100 <10 injections in last year 4 years since Wet AMD diagnosis; 50490 γ/ο PED <400um; no macular atrophy PCIOL [/av_toggle] [av_toggle title='Treatment Naïve/Previously Treated Wet AMD' title_open='' tags='' title_pos='' slide_speed='' custom_id='' aria_collapsed='' aria_expanded='' av_uid='av-29tuhu' sc_version='1.0'] Sponsor: Eyepoint Lugano Study Study Drug: Sustained-release Tyrosine Kinase Inhibitor (Intravitreal Injection) Control Arm: Afilbercept Inclusion/Exclusion Criteria: 50v/o BCVA-20/32-20/200 >2 injections in last 6 months CST <500um No Atrophy or scarring centrally [/av_toggle] [av_toggle title='Treatment naive/Previously treated Diabetic Macular Edema' title_open='' tags='' title_pos='' slide_speed='' custom_id='' aria_collapsed='' aria_expanded='' av_uid='av-l3xxde' sc_version='1.0'] Sponsor: Oculis Diamond Study Study Drug: Topical dexamethasone drops Control Arm: Sham 18-85y/o Inclusion/Exclusion Criteria: BCVA 20/50-20/320 in study eye; 20/40-20/200 fellow eye CST-310um Washout: >3 month anti-VEGF; 6 month Ozurdex No steroids (topical, oral, IM, IV, nasal) in last month
No contact lens users
RegenxBio – RGX-314-2202
A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space (SCS) Injections in Participants with Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE).
Diabetic Retinopathy w/ & w/o DME
Sponsor: Regenexbio
Study Drug: Suprachoroidal Gene Therapy (coding for Ranibizumab) (Suprachoroidal Injection)
Control Arm: Aflibercept
Inclusion/Exclusion Criteria: 25-89y/o
BCVA- 20/32-20/320 in study eye;
Mod NPDR-Early PDR
CST>325um (in DME arm)
Washout: >6month anti-VEGF/steroid <10 injections in last 3 years
H/o PRP or surgery
DME > 7 years
Upcoming Studies
Regeneron GA – Subcutaneous monthly injection of anti-complement agent
Astellas GA- Phase 4 observational study of patients receiving Izervay treatment
Genentech DME Tiež activator in combo with Aflibercept/Farcimab
Advarum Wet AMD Intravitreal injection of genetherapy coding for Aflibercept
Clinical Trials Information
Learn More About Clinical Trials
Find out more about our Retinal Research Institute or give us a call with any questions related to our studies and trials.
(602) 222-2221
Follow Us On Social
